Edition:
United Kingdom

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.80USD
15 Jun 2018
Change (% chg)

$0.05 (+0.87%)
Prev Close
$5.75
Open
$5.70
Day's High
$5.90
Day's Low
$5.64
Volume
12,520
Avg. Vol
12,836
52-wk High
$8.48
52-wk Low
$4.75

Latest Key Developments (Source: Significant Developments)

Mesoblast Appoints Josh Muntner As Its New CFO
Wednesday, 30 May 2018 

May 31 (Reuters) - Mesoblast Ltd ::APPOINTS JOSH MUNTNER AS ITS NEW CHIEF FINANCIAL OFFICER.MUNTNER TO REPLACE PAUL HODGKINSON.  Full Article

Mesoblast Posts Qtrly Loss Attributable $21.1 Million
Wednesday, 30 May 2018 

May 31 (Reuters) - Mesoblast Ltd ::QTRLY REVENUE $1.1 MILLION VERSUS $901,000 .QTRLY LOSS ATTRIBUTABLE $21.1 MILLION VERSUS LOSS $9.8 MILLION."THERE IS UNCERTAINTY RELATED TO GROUP'S ABILITY TO PARTNER PROGRAMS, RAISE CAPITAL OR DEBT AT TERMS TO MEET GROUP'S REQUIREMENTS".THERE IS UNCERTAINTY RELATED TO CO'S ABILITY TO SUSTAINABLY MAINTAIN IMPLEMENTED COST REDUCTIONS AND FURTHER DEFER PROGRAMS ON TIMELY BASIS.  Full Article

Mesoblast To Develop Cell-Based Immunotherapies For Solid Cancers With Cartherics
Tuesday, 29 May 2018 

May 29 (Reuters) - Mesoblast Ltd ::PARTNERS WITH CARTHERICS TO DEVELOP 'OFF-THE-SHELF' CELL-BASED IMMUNOTHERAPIES FOR SOLID CANCERS.PROGRAM WILL BE FUNDED BY A$12.6 MILLION FROM COLLABORATORS IN AUSTRALIAN GOVERNMENT'S COOPERATIVE RESEARCH CENTRES PROGRAM.  Full Article

Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Mesoblast Ltd ::‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​.  Full Article

Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mesoblast Ltd ::MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT.MESOBLAST LTD - TOP-LINE RESULTS FROM PHASE 3 TRIAL ARE EXPECTED IN Q1 2018.  Full Article

Tigenix Announces Grant From Mesoblast Of Exclusive Global Patent License In Local Treatment Of Fistulae
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Tigenix Nv ::MESOBLAST GRANTS TIGENIX AN EXCLUSIVE GLOBAL PATENT LICENSE TO USE ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN THE LOCAL TREATMENT OF FISTULAE (EN).AGREEMENT INCLUDES RIGHT FOR CO TO GRANT SUB-LICENSES TO AFFILIATES AND THIRD PARTIES.MESOBLAST WILL RECEIVE SINGLE DIGIT ROYALTIES ON NET SALES OF CX601.MESOBLAST WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS.  Full Article

Mesoblast Says Granted Tigenix Access To Certain Of Its Patents
Thursday, 14 Dec 2017 

Dec 15 (Reuters) - Mesoblast Ltd ::CO WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS ​.‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​.  Full Article

Mesoblast says ‍qtrly loss attributable $7 mln
Tuesday, 14 Nov 2017 

Nov 15 (Reuters) - Mesoblast Ltd ::‍Qtrly loss attributable $7 million versus loss of $19.8 million.Qtrly revenue $1.2 million versus $395,000‍​.  Full Article

MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Mesoblast Ltd ::MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS.‍INFUSIONS WERE WELL-TOLERATED AND THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED DURING 52-WEEK PERIOD IN TRIAL​.  Full Article

Mesoblast appoints Bill Burns as vice chairman
Thursday, 1 Sep 2016 

Mesoblast Ltd :Mesoblast appoints Bill Burns as vice chairman Full Article

BRIEF-Mesoblast ‍Enters $75 Mln Non-Dilutive Credit Facility

* ENTERED US$75 MILLION NON-DILUTIVE, FOUR-YEAR CREDIT FACILITY WITH HERCULES CAPITAL